DOUBLE BLIND, PLACEBO CONTROLLED TRIAL OF LJP 394 IN PATIENTS W/ SLE

在SLE患者中，双链DNA（dsDNA）抗体的存在与狼疮肾炎相关，这是一个预后不良的指标。LJP 394是一种研究性新药，开发用于治疗SLE和相关肾脏疾病。 它是一种独特的特异性B淋巴细胞耐受原，可抑制抗dsDNA抗体的产生。 这项多中心试验的目的是确定不同剂量的LJP 394对SLE患者抗dsDNA浓度的影响。

In patients with SLE, the presence of antibodies to double-stranded DNA (dsDNA) is associated with lupus nephritis, which is a poor prognostic indicator. LJP 394 is an investigational new drug developed as a treatment for SLE and associated renal disease. It is a unique, specific, B lymphocyte toleragen that arrests the production of anti-dsDNA antibodies. The objective of this multicenter trial is to determine the effect of different doses of LJP 394 on the anti-dsDNA concentration in patients with SLE.